Funding for this research was provided by:
National Science Foundation (DGE-1256082)
National Institutes of Health (U54 GM111274)
Gobernacion de Cordoba (754/2013)
National Institutes of Health (R35 GM119774-01)
Received: 9 May 2019
Accepted: 16 October 2019
First Online: 12 November 2019
Ethics approval and consent to participate
: In Colombia, most ZIKV diagnostic testing occurred at the INS. However, Colombian academics were also involved in ZIKV surveillance, sampling <i>Ae. aegypti</i> and limited human cases. Our study includes samples collected by both the INS and the Universidad del Rosario (UR). Sample collection by UR was approved by the Universidad del Rosario Ethics Committee, approval number 617-2017. Written consent was obtained for human specimen collection. Sample collection performed by the INS was approved by the Comité de Ética y Metodologías de la Investigación (CEMIN) - Instituto Nacional de Salud, approval number CEMIN 39-2017. Consent for specimen collection was waived as specimens were collected as part of the Colombian public health response. All sample selection for inclusion in the genomic analysis, sequencing library preparation, and data analysis were performed on anonymized samples and data. Administrative permission to access data collected by the INS was required. This permission was granted in Collaboration Agreement Fred-Hutch-Ref-#COL171204.
: Not applicable.
: The authors declare no competing interests.